{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:49:21Z","timestamp":1789130961791,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82370463"],"award-info":[{"award-number":["82370463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of the Guangxi Zhuang Autonomous Region","award":["2024GXNSFAA010154"],"award-info":[{"award-number":["2024GXNSFAA010154"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2025A1515012522"],"award-info":[{"award-number":["2025A1515012522"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M761313"],"award-info":[{"award-number":["2024M761313"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Technical Innovation Project of Guilin in Guangxi Zhuang Autonomous Region","award":["20210222-3"],"award-info":[{"award-number":["20210222-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02774-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:32:34Z","timestamp":1774420354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AIBP deficiency drives MAFLD advancement via ITG\u03b23 mediated lipid metabolism disruption and pro-inflammatory activation"],"prefix":"10.1186","volume":"24","author":[{"given":"Weiqian","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"24","key":"2774_CR1","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","volume":"23","author":"X Guo","year":"2022","unstructured":"Guo X, et al. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int J Mol Sci. 2022;23(24):15489.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2774_CR2","doi-asserted-by":"publisher","first-page":"2289830","DOI":"10.1080\/21688370.2023.2289830","volume":"12","author":"S Singh","year":"2024","unstructured":"Singh S, et al. Curative role of natural PPARgamma agonist in non-alcoholic fatty liver disease (NAFLD). Tissue Barriers. 2024;12(3):2289830.","journal-title":"Tissue Barriers"},{"issue":"1","key":"2774_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/biom15010140","volume":"15","author":"X Wan","year":"2025","unstructured":"Wan X, et al. Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs. Biomolecules. 2025;15(1):140.","journal-title":"Biomolecules"},{"key":"2774_CR4","doi-asserted-by":"publisher","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","volume":"13","author":"L Rong","year":"2022","unstructured":"Rong L, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2774_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"2774_CR6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/liv.15404","volume":"42","author":"VW Wong","year":"2022","unstructured":"Wong VW, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42(11):2377\u201389.","journal-title":"Liver Int"},{"issue":"2","key":"2774_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola R, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci. 2023;24(2):1703.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2774_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"2774_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705.","journal-title":"Gut"},{"issue":"11","key":"2774_CR10","doi-asserted-by":"publisher","first-page":"107876","DOI":"10.1016\/j.jbc.2024.107876","volume":"300","author":"P Liu","year":"2024","unstructured":"Liu P, et al. Ubiquitin-specific peptidase 25 ameliorates hepatic steatosis by stabilizing peroxisome proliferator-activated receptor alpha. J Biol Chem. 2024;300(11):107876.","journal-title":"J Biol Chem"},{"issue":"38","key":"2774_CR11","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","volume":"24","author":"M Papatheodoridi","year":"2018","unstructured":"Papatheodoridi M, et al. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2018;24(38):4574\u201386.","journal-title":"Curr Pharm Des"},{"key":"2774_CR12","doi-asserted-by":"publisher","first-page":"104733","DOI":"10.1016\/j.yexmp.2021.104733","volume":"124","author":"H Ahmed","year":"2022","unstructured":"Ahmed H, et al. TGF-beta1 signaling can worsen NAFLD with liver fibrosis backdrop. Exp Mol Pathol. 2022;124:104733.","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"2774_CR13","doi-asserted-by":"publisher","first-page":"103910","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei S, et al. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. 2024;29(3):103910.","journal-title":"Drug Discov Today"},{"key":"2774_CR14","doi-asserted-by":"publisher","first-page":"1386905","DOI":"10.3389\/fimmu.2024.1386905","volume":"15","author":"X Luo","year":"2024","unstructured":"Luo X, et al. Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease. Front Immunol. 2024;15:1386905.","journal-title":"Front Immunol"},{"issue":"8","key":"2774_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford BL, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671\u201384.","journal-title":"Cell Metab"},{"issue":"12","key":"2774_CR16","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.3390\/cells10123306","volume":"10","author":"W Zhu","year":"2021","unstructured":"Zhu W, et al. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells. 2021;10(12):3306.","journal-title":"Cells"},{"issue":"5","key":"2774_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, et al. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40(5):1367\u201393.","journal-title":"Endocr Rev"},{"issue":"2","key":"2774_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan N, et al. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236\u201352.","journal-title":"Cell Metab"},{"issue":"2","key":"2774_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","volume":"49","author":"E Cobbina","year":"2017","unstructured":"Cobbina E, et al. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197\u2013211.","journal-title":"Drug Metab Rev"},{"key":"2774_CR20","doi-asserted-by":"publisher","first-page":"103385","DOI":"10.1016\/j.redox.2024.103385","volume":"77","author":"H Jian","year":"2024","unstructured":"Jian H, et al. Branched-chain amino acids alleviate NAFLD via inhibiting de novo lipogenesis and activating fatty acid beta-oxidation in laying hens. Redox Biol. 2024;77:103385.","journal-title":"Redox Biol"},{"issue":"6","key":"2774_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"17","key":"2774_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u201358.","journal-title":"N Engl J Med"},{"issue":"2","key":"2774_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cells13020198","volume":"13","author":"S Choi","year":"2024","unstructured":"Choi S, et al. AIBP: A New Safeguard against Glaucomatous Neuroinflammation. Cells. 2024;13(2):198.","journal-title":"Cells"},{"issue":"19","key":"2774_CR24","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.3390\/ijms251910314","volume":"25","author":"JD Kim","year":"2024","unstructured":"Kim JD, et al. Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease. Int J Mol Sci. 2024;25(19):10314.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2774_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12967-019-1910-7","volume":"17","author":"T Zhang","year":"2019","unstructured":"Zhang T, et al. AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux. J Transl Med. 2019;17(1):161.","journal-title":"J Transl Med"},{"key":"2774_CR26","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.redox.2020.101703","volume":"37","author":"SH Choi","year":"2020","unstructured":"Choi SH, et al. AIBP protects retinal ganglion cells against neuroinflammation and mitochondrial dysfunction in glaucomatous neurodegeneration. Redox Biol. 2020;37:101703.","journal-title":"Redox Biol"},{"issue":"9","key":"2774_CR27","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/nutrit\/nuaf021","volume":"83","author":"R Li","year":"2025","unstructured":"Li R, et al. The Roles of Apolipoprotein A1-Binding Protein in Metabolic Diseases. Nutr Rev. 2025;83(9):1800\u20137.","journal-title":"Nutr Rev"},{"issue":"1","key":"2774_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12974-024-03214-4","volume":"21","author":"YS Kim","year":"2024","unstructured":"Kim YS, et al. AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2024;21(1):245.","journal-title":"J Neuroinflammation"},{"key":"2774_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2018.03.010","volume":"273","author":"M Zhang","year":"2018","unstructured":"Zhang M, et al. AIBP reduces atherosclerosis by promoting reverse cholesterol transport and ameliorating inflammation in apoE(-\/-) mice. Atherosclerosis. 2018;273:122\u201330.","journal-title":"Atherosclerosis"},{"issue":"2","key":"2774_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/art.42984","volume":"77","author":"G Lee","year":"2025","unstructured":"Lee G, et al. Enhancement of Intracellular Cholesterol Efflux in Chondrocytes Leading to Alleviation of Osteoarthritis Progression. Arthritis Rheumatol. 2025;77(2):151\u201362.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2774_CR31","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/antiox13101252","volume":"13","author":"S Choi","year":"2024","unstructured":"Choi S, et al. AIBP Protects M\u00fcller Glial Cells Against Oxidative Stress-Induced Mitochondrial Dysfunction and Reduces Retinal Neuroinflammation. Antioxid (Basel). 2024;13(10):1252.","journal-title":"Antioxid (Basel)"},{"issue":"2","key":"2774_CR32","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1161\/ATVBAHA.120.315485","volume":"41","author":"SH Choi","year":"2021","unstructured":"Choi SH, et al. Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density Lipoprotein)-Induced Mitophagy in Macrophages. Arterioscler Thromb Vasc Biol. 2021;41(2):e82\u201396.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2774_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.diabres.2018.06.017","volume":"142","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, et al. Epigallocatechin gallate improves insulin resistance in HepG2 cells through alleviating inflammation and lipotoxicity. Diabetes Res Clin Pract. 2018;142:363\u201373.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2774_CR34","doi-asserted-by":"publisher","first-page":"e0243938","DOI":"10.1371\/journal.pone.0243938","volume":"16","author":"N Zhao","year":"2021","unstructured":"Zhao N, et al. Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes. PLoS ONE. 2021;16(1):e0243938.","journal-title":"PLoS ONE"},{"issue":"3","key":"2774_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.gastro.2022.11.019","volume":"164","author":"AR Oh","year":"2023","unstructured":"Oh AR, et al. Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization. Gastroenterology. 2023;164(3):439\u201353.","journal-title":"Gastroenterology"},{"issue":"1","key":"2774_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1186\/s12967-024-05621-w","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, et al. VEGFB ameliorates insulin resistance in NAFLD via the PI3K\/AKT signal pathway. J Transl Med. 2024;22(1):976.","journal-title":"J Transl Med"},{"issue":"6","key":"2774_CR37","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.7150\/ijbs.92337","volume":"20","author":"YC Wu","year":"2024","unstructured":"Wu YC, et al. NUP85 alleviates lipid metabolism and inflammation by regulating PI3K\/AKT signaling pathway in nonalcoholic fatty liver disease. Int J Biol Sci. 2024;20(6):2219\u201335.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2774_CR38","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41467-023-37142-3","volume":"14","author":"Q Ye","year":"2023","unstructured":"Ye Q, et al. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K\/AKT\/PDGF axis activation in male mice. Nat Commun. 2023;14(1):1402.","journal-title":"Nat Commun"},{"issue":"4","key":"2774_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.7150\/ijbs.39414","volume":"16","author":"L Wei","year":"2020","unstructured":"Wei L, et al. Integrin \u03b23 promotes cardiomyocyte proliferation and attenuates hypoxia-induced apoptosis via regulating the PTEN\/Akt\/mTOR and ERK1\/2 pathways. Int J Biol Sci. 2020;16(4):644\u201354.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2774_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10020-022-00547-9","volume":"28","author":"H Li","year":"2022","unstructured":"Li H, et al. miR-351 promotes atherosclerosis in diabetes by inhibiting the ITGB3\/PIK3R1\/Akt pathway and induces endothelial cell injury and lipid accumulation. Mol Med. 2022;28(1):120.","journal-title":"Mol Med"},{"issue":"1","key":"2774_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00018-024-05526-3","volume":"82","author":"W Yao","year":"2024","unstructured":"Yao W, et al. Platelet stimulation-regulated expression of ILK and ITGB3 contributes to intrahepatic cholangiocarcinoma progression through FAK\/PI3K\/AKT pathway activation. Cell Mol Life Sci. 2024;82(1):19.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"2774_CR42","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41374-019-0281-2","volume":"99","author":"H Wan","year":"2019","unstructured":"Wan H, et al. Thy-1 depletion and integrin \u03b23 upregulation-mediated PI3K-Akt-mTOR pathway activation inhibits lung fibroblast autophagy in lipopolysaccharide-induced pulmonary fibrosis. Lab Invest. 2019;99(11):1636\u201349.","journal-title":"Lab Invest"},{"key":"2774_CR43","doi-asserted-by":"publisher","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","volume":"111S","author":"N Perakakis","year":"2020","unstructured":"Perakakis N, et al. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism. 2020;111S:154320.","journal-title":"Metabolism"},{"issue":"7","key":"2774_CR44","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1194\/jlr.C086512","volume":"59","author":"H Chen","year":"2018","unstructured":"Chen H, et al. AIBP, inflammation, and atherosclerosis. J Lipid Res. 2018;59(7):1081\u20133.","journal-title":"J Lipid Res"},{"issue":"8","key":"2774_CR45","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s11010-020-04037-6","volume":"476","author":"AO Jackson","year":"2021","unstructured":"Jackson AO, et al. Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem. 2021;476(8):3065\u201378.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"2774_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-023-01539-9","volume":"8","author":"C Lee","year":"2023","unstructured":"Lee C, et al. VEGF-B prevents excessive angiogenesis by inhibiting FGF2\/FGFR1 pathway. Signal Transduct Target Ther. 2023;8(1):305.","journal-title":"Signal Transduct Target Ther"},{"issue":"Pt 2","key":"2774_CR47","doi-asserted-by":"publisher","first-page":"130782","DOI":"10.1016\/j.ijbiomac.2024.130782","volume":"264","author":"L Lang","year":"2024","unstructured":"Lang L, et al. Knockdown of the VEGFB\/VEGFR1 signaling suppresses pubertal mammary gland development of mice via the inhibition of PI3K\/Akt pathway. Int J Biol Macromol. 2024;264(Pt 2):130782.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"2774_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, et al. AKT\/PKB Signaling: Navigating the Network. Cell. 2017;169(3):381\u2013405.","journal-title":"Cell"},{"key":"2774_CR49","doi-asserted-by":"publisher","first-page":"155743","DOI":"10.1016\/j.phymed.2024.155743","volume":"130","author":"H Zhao","year":"2024","unstructured":"Zhao H, et al. Phlorizin from Lithocarpus litseifolius [Hance]Chun ameliorates FFA-induced insulin resistance by regulating AMPK\/PI3K\/AKT signaling pathway. Phytomedicine. 2024;130:155743.","journal-title":"Phytomedicine"},{"issue":"1","key":"2774_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s10020-024-00889-6","volume":"30","author":"Z Lv","year":"2024","unstructured":"Lv Z, et al. RNA-binding protein GIGYF2 orchestrates hepatic insulin resistance through STAU1\/PTEN-mediated disruption of the PI3K\/AKT signaling cascade. Mol Med. 2024;30(1):124.","journal-title":"Mol Med"},{"issue":"5","key":"2774_CR51","doi-asserted-by":"publisher","first-page":"112530","DOI":"10.1016\/j.celrep.2023.112530","volume":"42","author":"S Fujinuma","year":"2023","unstructured":"Fujinuma S, et al. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation. Cell Rep. 2023;42(5):112530.","journal-title":"Cell Rep"},{"issue":"49","key":"2774_CR52","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020;117(49):31189\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2774_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","volume":"22","author":"D Gu","year":"2024","unstructured":"Gu D, et al. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms. J Transl Med. 2024;22(1):93.","journal-title":"J Transl Med"},{"key":"2774_CR54","doi-asserted-by":"publisher","first-page":"155382","DOI":"10.1016\/j.phymed.2024.155382","volume":"126","author":"L Chen","year":"2024","unstructured":"Chen L, et al. Artesunate improves glucose and lipid metabolism in db\/db mice by regulating the metabolic profile and the MAPK\/PI3K\/Akt signalling pathway. Phytomedicine. 2024;126:155382.","journal-title":"Phytomedicine"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02774-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:02:22Z","timestamp":1777888942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02774-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02774-7","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}